The U.S. small molecule contract development and manufacturing organization (CDMO) market is entering a period of robust growth, propelled by a strategic surge in outsourcing from pharmaceutical and biotechnology firms. According to the latest market intelligence report, the U.S. small molecule CDMO market size reached approximately $26.85 billion in 2024 and is projected to almost double, attaining $47.38 billion by 2033 with a compound annual growth rate (CAGR) of 6.68% from 2025 to 2033. This growth underscores an industry-wide shift as pharmaceutical companies, particularly small and mid-sized enterprises as well as virtual biotechs, increasingly depend on CDMOs for expertise in formulation, process development, regulatory compliance, and risk mitigation.

A key driver for this expansion is the persistent demand for small molecule drugs within the U.S. pharmaceutical landscape. In 2023, over 60% of new molecular entities (NMEs) approved by the FDA were small molecules, highlighting their ongoing dominance in drug development pipelines. Notable approvals—such as Ogsiveo, targeting desmoid tumors, and Zurzuvae, designed for postpartum depression—exemplify the diversity of therapeutic areas fueling demand. Early-stage R&D actors, most without internal manufacturing capabilities, increasingly rely on CDMOs to cover preclinical to commercial-scale production, fostering a deep integration of outsourcing in the drug development lifecycle.

Cost pressures and the need for operational agility further motivate both innovator and generic drug companies to streamline internal infrastructures and focus on core competencies, offloading manufacturing and related technical functions. CDMOs in the U.S. are responding through significant investments in capacity expansion, technological innovation, and green chemistry initiatives. For instance, Cambrex's recent investment of over $50 million in its North Carolina facility aims to scale up process development and active pharmaceutical ingredient (API) manufacturing for small molecules, reinforcing its competitive edge. Similarly, Thermo Fisher Scientific has broadened its U.S. network and upgraded facilities after acquiring Patheon, enabling a comprehensive service offering across the value chain.

Another catalyst is the regulatory and logistical advantage for U.S.-based CDMOs. Manufacturing domestically streamlines the compliance process, especially regarding FDA current Good Manufacturing Practices (cGMP), and reduces supply chain complexity. This compliance assurance is particularly attractive to both domestic innovators and international biopharma clients seeking access to the U.S. market. The competitive landscape is marked by ongoing consolidation, with larger CDMOs enhancing their offerings to support scaling needs, regulatory filings, and accelerated timelines for high-value therapeutics, notably in oncology, rare diseases, and central nervous system (CNS) indications.

The ongoing wave of outsourcing reflects a strategic realignment within the life sciences, with companies seeking to optimize R&D expenditures, access specialist manufacturing solutions, and accelerate time-to-market. The marketplace is poised for continued dynamism through 2033, as U.S. small molecule CDMOs invest in continuous manufacturing, digitalization, sustainable operations, and capabilities expansion—a trend that promises to reshape the pharma manufacturing outsourcing model for years to come. Stakeholders—from executive leadership teams and R&D portfolio strategists to procurement and operations managers—must monitor these developments closely, as the landscape offers both competitive opportunities and challenges in the evolving U.S. pharmaceutical manufacturing sector.